In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
|Articles|February 1, 2008
- Applied Clinical Trials-02-01-2008
- Volume 0
- Issue 0
Advertising Exhibitors Gallery
Advertising Exhibitors Gallery
Advertisement
Advertising Exhibitors Gallery
IIR's Clinical Trials Congress
February 2527, 2008
Loews Royal Pacific Resort, Orlando, FL
ALMAC Clinical Technologies
Booth Number: 408
1040 Stony Hill Road
Suite 200
Yardley, PA 19067
Phone: 267-685-4284
Email:
www:
EResearchTechnology, Inc.
Booth Number: 207
30 South 17th Street
Philadelphia, PA 19103
Phone: 215-972-0420
Fax:215-972-0414
Email:
www:
MedNet Solutions, Inc.
Booth Number: 506
601 Carlson Parkway
Suite 605
Minnetonka, MN 55305
Phone: 763-258-2735
Fax: 763-258-2737
Email:
www:
United BioSource Corporation
Booth Number: 505
7501 Wisconsin Avenue
Suite 705
Bethesda, MD 20814
Phone: 866-458-1096
Fax: 240-644-0421
Email:
www:
Articles in this issue
over 18 years ago
How Technology Could Change Drug Approvalsover 18 years ago
India Benefits from SMO Presenceover 18 years ago
eShowcase: Company Introduces and Validated Productsover 18 years ago
Pharmacovigilance: A Company-Wide Challengeover 18 years ago
eShowcase: Web Submission Data Manager Updatedover 18 years ago
Limited Resources Undermine FDAAdvertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Where AI Governance in Clinical Development Falls Short
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5